Vermillion, Inc. has received a notice of allowance from the United States Patent and Trademark Office for a patent, "Biomarkers for Ovarian Cancer."
The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer monitoring, and patient management.
This represents the fifteenth biomarker patent granted or allowed for Vermillion, four of which support the company's ovarian cancer franchise and its flagship product, OVA1®.
"Our innovative biomarker research continues to build Vermillion's platform of proprietary diagnostic tools, which is supported by key patents," said Donald Munroe, Ph.D., the company's chief science officer and VP of research & development.
Munroe continued, "We believe these tools represent the best diagnostic tools available today in the diagnosis and management of ovarian cancer, which is the leading cause of gynecologic cancer mortality."